This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Recent cases of anti-Peruvianism were seen in 2000, as the magazine La Primera denounced a "silent invasion" of Peruvians and Bolivians, with a cover illustrating a dark-skinned man with a missing tooth (through Photoshop) to increase the ideological content of the note or in 2010 when the newspaper La Nación denounced an invasion of Bolivians, Peruvians and Paraguayans in Argentina, which unleashed a wave of xenophobic and racist comments from readers.
Due to PTT activity in hypoxic environments, it may be also used on more developed tumors than PDT. Low-temperature PTT (≤ 45 °C) for treatment of infections is also a possibility when combined with an antibiotic compound due to heat's proportionality with membrane permeability - a hotter environment causes heightened membrane permeability, which thus allows the drug into the cell. This would reduce/eliminate the impact on human cell viability, and aiding in antibiotic accumulation within the target cell may assist in restoring activity in antibiotics that pathogens had developed resistance to. PTT is typically seen to have improved antimicrobial and wound healing activity when combined with an additional mechanism of action through PDT or added antibiotic compounds in the application.
==== United Kingdom and Ireland ==== Tim Hortons' products have been available in Ireland and the United Kingdom at some Spar convenience stores since 2006 and Tesco supermarkets. Tim Hortons' other international expansions include a small outlet at the Dublin Zoo. Tim Hortons coffee and donuts were being sold at small self-service counters in 50 Spar stores in the UK and Ireland as of April 30, 2007.
His contemporary Alfred Russel Wallace also noted these variations and the geographical separations between different forms leading to the study of biogeography. Wallace was influenced by the work of Philip Lutley Sclater on the distribution patterns of birds.
=== EC 2.1.2: Hydroxymethyl-, Formyl- and Related Transferases === EC 2.1.2.1: glycine hydroxymethyltransferase EC 2.1.2.2: phosphoribosylglycinamide formyltransferase 1 EC 2.1.2.3: phosphoribosylaminoimidazolecarboxamide formyltransferase EC 2.1.2.4: glycine formimidoyltransferase EC 2.1.2.5: glutamate formiminotransferase EC 2.1.2.6: deleted, included in EC 2.1.2.5 EC 2.1.2.7: D-alanine 2-hydroxymethyltransferase EC 2.1.2.8: deoxycytidylate 5-hydroxymethyltransferase EC 2.1.2.9: methionyl-tRNA formyltransferase EC 2.1.2.10: aminomethyltransferase EC 2.1.2.11: 3-methyl-2-oxobutanoate hydroxymethyltransferase EC 2.1.2.12: now EC 2.1.1.74 EC 2.1.2.13: UDP-4-amino-4-deoxy-L-arabinose formyltransferase EC 2.1.2.14: GDP-perosamine N-formyltransferase
Sources: en.wikipedia.org
== Autophosphorylation == Autophosphorylation is the process in which a kinase attaches a phosphate group to itself. When CaMKII autophosphorylates, it becomes persistently active. Phosphorylation of the Threonine 286 site allows for the activation of the catalytic domain. Autophosphorylation is enhanced by the structure of the holoenzyme because it is present in two stacked rings. The close proximity of these adjacent rings increases the probability of phosphorylation of neighboring CaMKII enzymes, furthering autophosphorylation. A mechanism that promotes autophosphorylation features inhibition of the PP1 (protein phosphatase I). This enables CaMKII to be constantly active by increasing the likelihood of autophosphorylation.
=== Clitoris === Located at the anterior junction of the labia minora is the clitoris, a highly erogenous sexual organ. The visible portions of the clitoris are the glans and frenulum. Typically, the glans is roughly the size and shape of a pea, and can vary in size from about 6 mm to 25 mm (less than an inch). The size can also vary when the clitoris is erect, which happens when two regions of erectile tissue known as the corpora cavernosa (along with the bulbs and crura, which both constitute the root of the clitoris) fill with blood, making the shaft engorged. The glans contains many nerve endings, which makes it highly sensitive. The only known function of the clitoris is to focus on sexual feelings. The clitoral hood is a protective fold of skin and it may partially or completely cover the shaft and glans. The hood may be partially or completely hidden within the pudendal cleft.
== Prevention == No prevention mechanism exists for Sjögren's disease (SjD) because of its complexity as an autoimmune disorder. However, lifestyle changes can reduce the risk factors related to developing SjD or reduce the severity of the condition for patients who have already been diagnosed. Diet is strongly associated with the inflammation seen in many autoimmune-related diseases, including SjD. An experimental study concluded that SjD patients often show high gluten sensitivity that directly relates to inflammation. Moderate exercise is also helpful in SjD patients, mainly reducing the effect of lung inflammation.
=== Flexible rechargeable battery electrode === Graphene oxide has been demonstrated as a flexible free-standing battery anode material for room temperature lithium-ion and sodium-ion batteries. It is also being studied as a high surface area conducting agent in lithium-sulfur battery cathodes. The functional groups on graphene oxide can serve as sites for chemical modification and immobilization of active species. This approach allows for the creation of hybrid architectures for electrode materials. Recent examples of this have been implemented in lithium-ion batteries, which are known for being rechargeable at the cost of low capacity limits. Graphene oxide-based composites functionalized with metal oxides and sulfides have been shown in recent research to induce enhanced battery performance. This has similarly been adapted into applications in supercapacitors, since the electronic properties of graphene oxide allow it to bypass some of the more prevalent restrictions of typical transition metal oxide electrodes. Research in this field is developing, with additional exploration into methods involving nitrogen doping and pH adjustment to improve capacitance. Additionally, research into reduced graphene oxide sheets, which display superior electronic properties akin to pure graphene, is currently being explored. Reduced graphene oxide greatly increases the conductivity and efficiency, while sacrificing some flexibility and structural integrity.
Sources: en.wikipedia.org
== Protein == Sex hormone-binding globulin is homodimeric, meaning it has two identical peptide chains making up its structure. The amino acid sequence is the same as for androgen-binding protein produced in testes, but with different oligosaccharides attached. SHBG has two laminin G-like domains which form pockets that bind hydrophobic molecules. The steroids are bound by the LG domain at the amino end of the protein. Inside the pocket of the domain is a serine residue that attracts the two different types of steroids at different points, thus changing their orientation. Androgens bind at the C3 functional groups on the A ring, and estrogens bind via a hydroxyl attached to C17 on the D ring. The two different orientations change a loop over the entrance to the pocket and the position of trp84 (in humans). Thus the whole protein signals what hormone it carries on its own surface. The steroid binding LG domain is coded by exons 2 to 5. A linker region joins the two LG domains together. When first produced, the SHBG precursor has a leading signal peptide attached with 29 amino acids. The remaining peptide has 373 amino acids. There are two sulfur bridges. The sugars are attached at two different N-glycosylation points on asparagine (351 and 367) and one O-glycosylation point (7) on threonine.
== History == Chlordiazepoxide (initially called methaminodiazepoxide) was the first benzodiazepine to be synthesized in the mid-1950s. The synthesis was derived from work on a class of dyes, quinazoline-3-oxides. It was discovered by accident when in 1957 tests revealed that the compound had hypnotic, anxiolytic, and muscle relaxant effects. "The story of the chemical development of Librium and Valium was told by Sternbach. The serendipity involved in the invention of this class of compounds was matched by the trials and errors of the pharmacologists in the discovery of the tranquilizing activity of the benzodiazepines. The discovery of Librium in 1957 was due largely to the dedicated work and observational ability of a gifted technician, Beryl Kappell. For some seven years she had been screening compounds by simple animal tests for muscle relaxant activity using Myanesin as a standard and then meprobamate and chlorpromazine when they became available. All compounds submitted by the chemical staff for central nervous activity were screened. It was this battery of tests that picked out RO 5-0690 (Librium, chlordiazepoxide) as being similar but more potent than meprobamate." Three years later chlordiazepoxide was marketed as a therapeutic benzodiazepine medication under the brand name Librium. Following chlordiazepoxide, in 1963 diazepam hit the market under the brand name Valium—and was followed by many further benzodiazepine compounds over the subsequent years and decades. In 1959 it was used by over 2,000 physicians and more than 20,000 patients.
=== Biosimilars === Abasaglar was authorized for medical use in the European Union in September 2014. Lusduna was authorized for medical use in the European Union in January 2017. Semglee was authorized for medical use in the European Union in March 2018. Semglee (glargine-yfgn) was approved for medical use in the United States in July 2021. Rezvoglar (glargine-aglr) was approved for medical use in the United States in December 2021. In November 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ondibta, intended for the treatment of diabetes. The applicant for this medicinal product is Gan & Lee Pharmaceuticals Europe GmbH. Ondibta is a biosimilar medicinal product that is highly similar to the reference product Lantus, which was authorized in the EU in June 2000. Ondibta was authorized for medical use in the European Union in January 2026.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.